These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36764763)

  • 1. Synthesis of SNIPERs against BCR-ABL with kinase inhibitors and a method to evaluate their growth inhibitory activity derived from BCR-ABL degradation.
    Cho N; Naito M
    Methods Enzymol; 2023; 681():41-60. PubMed ID: 36764763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
    Shibata N; Miyamoto N; Nagai K; Shimokawa K; Sameshima T; Ohoka N; Hattori T; Imaeda Y; Nara H; Cho N; Naito M
    Cancer Sci; 2017 Aug; 108(8):1657-1666. PubMed ID: 28556300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.
    Shibata N; Shimokawa K; Nagai K; Ohoka N; Hattori T; Miyamoto N; Ujikawa O; Sameshima T; Nara H; Cho N; Naito M
    Sci Rep; 2018 Sep; 8(1):13549. PubMed ID: 30202081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
    Ma Z; Ji Y; Yu Y; Liang D
    Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
    J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
    Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
    Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.
    Shibata N; Ohoka N; Hattori T; Naito M
    Chem Pharm Bull (Tokyo); 2019; 67(3):165-172. PubMed ID: 30827996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.
    Demizu Y; Shibata N; Hattori T; Ohoka N; Motoi H; Misawa T; Shoda T; Naito M; Kurihara M
    Bioorg Med Chem Lett; 2016 Oct; 26(20):4865-4869. PubMed ID: 27666635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted protein degradation and drug discovery.
    Naito M
    J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SNIPERs-Hijacking IAP activity to induce protein degradation.
    Naito M; Ohoka N; Shibata N
    Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.
    Liu H; Mi Q; Ding X; Lin C; Liu L; Ren C; Shen S; Shao Y; Chen J; Zhou Y; Ji L; Zhang H; Bai F; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2022 Dec; 244():114810. PubMed ID: 36306539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.
    Tong B; Spradlin JN; Novaes LFT; Zhang E; Hu X; Moeller M; Brittain SM; McGregor LM; McKenna JM; Tallarico JA; Schirle M; Maimone TJ; Nomura DK
    ACS Chem Biol; 2020 Jul; 15(7):1788-1794. PubMed ID: 32568522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects.
    Tsukumo Y; Tsuji G; Yokoo H; Shibata N; Ohoka N; Demizu Y; Naito M
    Methods Mol Biol; 2021; 2365():331-347. PubMed ID: 34432253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
    Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
    Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
    Zhao Q; Ren C; Liu L; Chen J; Shao Y; Sun N; Sun R; Kong Y; Ding X; Zhang X; Xu Y; Yang B; Yin Q; Yang X; Jiang B
    J Med Chem; 2019 Oct; 62(20):9281-9298. PubMed ID: 31539241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.